Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5998921 | 1.00 | TGM2 (0.42) | TGM2PDGFRBALDH1A1SMN1; SMN2AURKB | |
| SCHEMBL4994797 | 0.96 | TGM2 (0.46) | TGM2PDGFRBALDH1A1AURKBAURKA | |
| SCHEMBL4994803 | 0.96 | TGM2 (0.46) | TGM2PDGFRBALDH1A1AURKBAURKA | |
| SCHEMBL4991200 | 0.95 | TGM2 (0.46) | TGM2PDGFRBALDH1A1SMN1; SMN2AURKB | |
| SCHEMBL4991197 | 0.95 | TGM2 (0.46) | TGM2PDGFRBALDH1A1SMN1; SMN2AURKB | |
| SCHEMBL4993082 | 0.91 | TGM2 (0.42) | TGM2PDGFRBALDH1A1AURKBAURKA | |
| SCHEMBL4993076 | 0.91 | TGM2 (0.42) | TGM2PDGFRBALDH1A1AURKBAURKA | |
| SCHEMBL4995436 | 0.89 | TGM2 (0.46) | TGM2PDGFRBALDH1A1SMN1; SMN2MDM2 | |
| SCHEMBL4995430 | 0.89 | TGM2 (0.46) | TGM2PDGFRBALDH1A1SMN1; SMN2MDM2 | |
| SCHEMBL4999070 | 0.88 | TGM2 (0.42) | TGM2PDGFRBALDH1A1SMN1; SMN2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060025413-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025413-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | TGM2 3215/4885PDGFRB 307/4885ALDH1A1 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.